Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline
G Raghu, M Remy-Jardin, JL Myers… - American journal of …, 2018 - atsjournals.org
Background: This document provides clinical recommendations for the diagnosis of
idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American …
idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American …
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management
G Raghu, HR Collard, JJ Egan, FJ Martinez… - American journal of …, 2011 - atsjournals.org
This document is an international evidence-based guideline on the diagnosis and management
of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic …
of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic …
[HTML][HTML] Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
L Richeldi, RM Du Bois, G Raghu… - … England Journal of …, 2014 - Mass Medical Soc
Background Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of …
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of …
An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial …
…, FJ Martinez, J Myers, S Protzko, G Raghu… - American journal of …, 2013 - atsjournals.org
Background: In 2002 the American Thoracic Society/European Respiratory Society (ATS/ERS)
classification of idiopathic interstitial pneumonias (IIPs) defined seven specific entities, …
classification of idiopathic interstitial pneumonias (IIPs) defined seven specific entities, …
Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline
G Raghu, M Remy-Jardin, L Richeldi… - American Journal of …, 2022 - atsjournals.org
… Ganesh Raghu … Ganesh Raghu … Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J,
Brown KK, et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/…
Brown KK, et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/…
Incidence and prevalence of idiopathic pulmonary fibrosis
G Raghu, D Weycker, J Edelsberg… - American journal of …, 2006 - atsjournals.org
Rationale: Idiopathic pulmonary fibrosis is a chronic interstitial lung disease of unknown
etiology; its epidemiology in the United States has not been well characterized. Objective: To …
etiology; its epidemiology in the United States has not been well characterized. Objective: To …
An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline
G Raghu, B Rochwerg, Y Zhang… - American journal of …, 2015 - atsjournals.org
Background: This document updates the American Thoracic Society/European Respiratory
Society/Japanese Respiratory Society/Latin American Thoracic Association guideline on …
Society/Japanese Respiratory Society/Latin American Thoracic Association guideline on …
Acute exacerbations of idiopathic pulmonary fibrosis
…, JE Loyd, I Noth, MA Olman, G Raghu… - American journal of …, 2007 - atsjournals.org
The natural history of idiopathic pulmonary fibrosis (IPF) has been characterized as a steady,
predictable decline in lung function over time. Recent evidence suggests that some …
predictable decline in lung function over time. Recent evidence suggests that some …
[HTML][HTML] Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis
…, KR Flaherty, PW Noble, G Raghu… - … England Journal of …, 2011 - Mass Medical Soc
Background Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality
rate. Because the signaling pathways activated by several tyrosine kinase receptors have …
rate. Because the signaling pathways activated by several tyrosine kinase receptors have …
[HTML][HTML] Nintedanib for systemic sclerosis–associated interstitial lung disease
…, A Fischer, MD Mayes, G Raghu… - … England Journal of …, 2019 - Mass Medical Soc
Background Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis
and a leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase …
and a leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase …